U.S. FDA approves Johnson & Johnson’s bladder cancer drug

(Reuters) – The U.S. Food and Drug Administration on Friday approved Johnson & Johnson’s treatment for patients with a form of bladder cancer.

The green signal to the drug, Balversa, makes it the first approved treatment for bladder cancer that targets a genetic alteration known as FGFR3 or FGFR2, the FDA said.